Stock Price Movement and Market Context
On 2 Mar 2026, Lasa Supergenerics Ltd’s share price fell by 5.32% to reach Rs.7.29, underperforming its sector by 4.51%. This decline follows a brief two-day rally, signalling a reversal in the short-term trend. The stock is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating sustained downward momentum.
In contrast, the broader market index, Sensex, despite opening sharply lower by 2,743.46 points, managed a partial recovery of 1,148.82 points to close at 79,692.55, down 1.96%. The Sensex remains below its 50-day moving average, though the 50DMA is positioned above the 200DMA, suggesting mixed signals for the broader market.
Long-Term Performance and Relative Weakness
Over the past year, Lasa Supergenerics Ltd has recorded a steep decline of 63.00%, a stark contrast to the Sensex’s positive return of 8.87% during the same period. The stock’s 52-week high was Rs.24.44, highlighting the extent of the recent depreciation. This underperformance is consistent with the company’s track record, as it has lagged behind the BSE500 index in each of the last three annual periods.
Fundamentals that don't lie! This Small Cap from Trading shows consistent growth and price strength over time. A reliable pick you can truly count on.
- - Strong fundamental track record
- - Consistent growth trajectory
- - Reliable price strength
Financial Metrics and Profitability Concerns
The company’s financial health remains under pressure, reflected in its Mojo Score of 3.0 and a recent downgrade from a Sell to a Strong Sell rating on 11 Feb 2025. The Market Cap Grade stands at 4, indicating a relatively small market capitalisation compared to peers.
Lasa Supergenerics Ltd reported net sales of Rs.25.27 crores for the nine months ending December 2025, representing a sharp contraction of 75.54% year-on-year. The quarterly profit after tax (PAT) was a loss of Rs.2.55 crores, down 17.3% compared to the previous period. These figures underscore the company’s challenges in generating revenue and maintaining profitability.
The company’s ability to service debt is notably weak, with an average EBIT to interest ratio of -5.16, signalling that earnings before interest and tax are insufficient to cover interest expenses. Return on equity (ROE) averages at 3.54%, indicating low profitability relative to shareholders’ funds.
Valuation and Risk Profile
Despite the negative price performance, the company’s profits have shown a rise of 101.8% over the past year, resulting in a price-to-earnings-to-growth (PEG) ratio of 0.4. However, the stock is considered risky relative to its historical valuations, reflecting investor caution amid ongoing financial strain.
The consistent underperformance against benchmark indices over the last three years further emphasises the challenges faced by Lasa Supergenerics Ltd in delivering shareholder value.
Is Lasa Supergenerics Ltd your best bet? SwitchER suggests better alternatives across peers, market caps, and sectors. Discover stocks that could deliver more for your portfolio!
- - Better alternatives suggested
- - Cross-sector comparison
- - Portfolio optimization tool
Shareholding and Sectoral Positioning
The majority shareholding of Lasa Supergenerics Ltd remains with the promoters, maintaining control over company decisions. The firm operates within the Pharmaceuticals & Biotechnology sector, which has seen mixed performance in recent months, with some peers outperforming the broader market indices.
Given the stock’s current position below all major moving averages and its recent 52-week low, the prevailing market sentiment reflects caution. The company’s financial indicators and relative performance metrics provide a comprehensive picture of the challenges it faces in regaining momentum.
Summary of Key Data Points
• New 52-week low and all-time low price: Rs.7.29
• Day change: -5.32%
• Underperformance vs sector: -4.51%
• 1-year stock return: -63.00%
• Sensex 1-year return: +8.87%
• Net sales (9M Dec 2025): Rs.25.27 crores (-75.54%)
• PAT (Quarterly): Rs.-2.55 crores (-17.3%)
• EBIT to interest ratio (avg): -5.16
• Return on equity (avg): 3.54%
• Mojo Score: 3.0 (Strong Sell)
• Market Cap Grade: 4
The stock’s recent decline to Rs.7.29 marks a significant milestone in its downward trajectory, reflecting a combination of subdued financial performance and broader market dynamics within the Pharmaceuticals & Biotechnology sector.
Only Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Start Today
